Join JYMed at CPHI China 2025

CPHI China 2025 will take place from June 24–26, 2025, at the Shanghai New International Expo Centre (SNIEC). Spanning more than 230,000 square meters, the event is set to host over 3,500 exhibitors and attract more than 100,000 industry professionals. As one of Asia’s largest and most influential pharmaceutical trade shows, CPHI China offers an unparalleled platform for networking, innovation, and business development.
 
About JYMed
 
JYMed is a high-tech pharmaceutical company focused on the research, development, manufacturing, and commercialization of peptide-based products. We also offer fully integrated CDMO services, delivering customized peptide solutions to pharmaceutical, cosmetic, and veterinary clients worldwide.
 
Our product portfolio includes dozens of peptide APIs. Flagship products such as Semaglutide and Tirzepatide have successfully completed U.S. FDA DMF filing.

Our wholly owned subsidiary, Hubei JXBio, operates state-of-the-art peptide API production lines built to meet cGMP standards set by both the U.S. FDA and China’s NMPA. The facility houses 10 large-scale and pilot-scale production lines, supported by a robust pharmaceutical Quality Management System (QMS) and a comprehensive Environmental Health and Safety (EHS) program.
 
JXBio has passed GMP inspections by both the U.S. FDA and China’s NMPA and is recognized by leading global pharmaceutical companies for excellence in EHS management, reflecting our commitment to quality, safety, and environmental stewardship.

MAIN PRODUCTS

Contact Us

For more information about our products and services, please reach out:
● Global API & Cosmetic Inquiries: +86-150-1352-9272
● API Registration & CDMO Services (U.S. & EU): +86-158-1868-2250
● Email: jymed@jymedtech.com
● Address: Floors 8 & 9, Building 1, Shenzhen Biomedical Innovation Industrial Park, 14 Jinhui Road, Kengzi Subdistrict, Pingshan District, Shenzhen, China.